{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:37:06Z","timestamp":1787647026863,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejim.2026.106852","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:24:43Z","timestamp":1774499083000},"page":"106852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Shaping rheumatoid arthritis treatment: Clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors. Insights from the AMBI-RA study"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2795-4141","authenticated-orcid":false,"given":"Riccardo","family":"Bertola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Maranini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Garaffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1791-0181","authenticated-orcid":false,"given":"Maria","family":"Pozzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Laura","family":"Riva Cambrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1696-3805","authenticated-orcid":false,"given":"Alessandro","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0499-5773","authenticated-orcid":false,"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-8134","authenticated-orcid":false,"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-8222","authenticated-orcid":false,"given":"Ettore","family":"Silvagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.106852_bib0001","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.ejim.2026.106852_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1398314","article-title":"Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy","volume":"15","author":"Perricone","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2026.106852_bib0005","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/nat8nl","article-title":"Novel insights into the management of rheumatoid arthritis: one year in review 2023","author":"Garaffoni","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0006","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/166dsf","article-title":"Novel insights into the management of rheumatoid arthritis: one year in review 2024","author":"Molteni","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0007","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.3390\/jcm12206690","article-title":"Janus Kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of Tofacitinib, Baricitinib and Upadacitinib","volume":"12","author":"Harrington","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0008","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","article-title":"Long-term persistence with rituximab in patients with rheumatoid arthritis","volume":"57","author":"Oldroyd","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2026.106852_bib0009","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejim.2026.106852_bib0011","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/S2665-9913(20)30001-1","article-title":"Tofacitinib\u2019s infectious profile: concerns for clinical practice","volume":"2","author":"Favalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0012","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with Baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0014","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0016","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0017","unstructured":"Updated recommendations to minimize the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi) (2023). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki."},{"key":"10.1016\/j.ejim.2026.106852_bib0018","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0019","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00228-022-03402-2","article-title":"JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study","volume":"78","author":"Gouverneur","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2026.106852_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0021","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the safety of TofAcitinib in routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0022","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with Baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","author":"Salinas","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ejim.2026.106852_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1565909","article-title":"Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles","volume":"16","author":"Silvagni","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2026.106852_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1225160","article-title":"The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events","volume":"14","author":"Favalli","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2026.106852_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102234","article-title":"A review of biosimilars for rheumatoid arthritis","volume":"64","author":"Conran","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ejim.2026.106852_bib0026","unstructured":"Giunta Regionale Emilia Romagna. Atti Amministrativi, Delibera num. 2117 del 05\/12\/2022, Seduta num. 50 - Approvazione del Bilancio Preventivo Economico Annuale per l\u2019esercizio 2022 della Gestione Sanitaria Accentrata Regionale ai sensi del Decreto Legislativo 23 giugno 2011, N. 118 E SS.MM.II. Available from: https:\/\/servizissiir.regione.emilia-romagna.it\/deliberegiunta\/servlet\/AdapterHTTP?action_name=ACTIONRICERCADELIBERE&operation=downloadTesto&codProtocollo=GPG\/2022\/2242&ENTE=1 n.d."},{"key":"10.1016\/j.ejim.2026.106852_bib0027","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2026.106852_bib0028","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.3390\/jcm10225460","article-title":"Comparison of indexes to measure comorbidity burden and predict all-cause mortality in rheumatoid arthritis","volume":"10","author":"Huang","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0029","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009742.2020.1855365","article-title":"Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECord-linkage on Rheumatic Disease study on administrative healthcare databases","volume":"50","author":"D\u2019Amico","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0031","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ejim.2026.106852_bib0032","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0033","unstructured":"R: the R Project for Statistical Computing n.d. https:\/\/www.r-project.org\/(accessed August 5, 2022)."},{"key":"10.1016\/j.ejim.2026.106852_bib0035","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2026.106852_bib0036","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2665-9913(24)00002-X","article-title":"The influence of safety warnings on the prescribing of JAK inhibitors","volume":"6","author":"Russell","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1445680","article-title":"Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study","volume":"15","author":"Strunz","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2026.106852_bib0038","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/acr2.11602","article-title":"Changes in patterns of use of advanced therapies following emerging data about adverse events in patients with rheumatoid arthritis from the Veterans Affairs Health System","volume":"5","author":"Jeong","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0039","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.3390\/jcm13133929","article-title":"Influence of safety warnings on the prescribing attitude of JAK inhibitors for rheumatoid arthritis in Italy","volume":"13","author":"Paroli","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0041","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/ard-2023-224670","article-title":"Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study)","volume":"83","author":"Aymon","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0042","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2665-9913(24)00033-X","article-title":"The Lancet rheumatology null. JAK inhibitors-friend or foe?","volume":"6","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0043","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/jcm12010207","article-title":"Characteristics of patients treated with JAK inhibitors in rheumatoid arthritis before versus after VTE risk warnings","volume":"12","author":"Philippoteaux","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0044","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2023-eular.4643","article-title":"POS1085 Initiation of a Janus Kinase inhibitor before and after the safety warnings: changes in characteristics of patients with rheumatoid arthritis","volume":"82","author":"Huschek","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/acr.25268","article-title":"Changes in characteristics of patients initiating and discontinuing advanced therapies for rheumatoid arthritis following the release of safety data","volume":"76","author":"Song","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejim.2026.106852_bib0046","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/acr.25356","article-title":"Prevalence of cardiovascular and cancer risk factors among rheumatoid arthritis patients prescribed JAK inhibitors and tumor necrosis factor inhibitors: a cross-sectional study","volume":"76","author":"Janak","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejim.2026.106852_bib0047","doi-asserted-by":"crossref","first-page":"10","DOI":"10.31138\/mjr.171023.rof","article-title":"Risk of major adverse cardiovascular events and venous thromboembolism with JAK inhibitors versus TNF inhibitors in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"35","author":"Partalidou","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0048","article-title":"The risk of malignancy and major adverse cardiovascular events with the use of janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis of real-world evidence [abstract]","volume":"76","author":"Haider","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0049","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/keae279","article-title":"Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK","volume":"64","author":"Tian","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2026.106852_bib0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-023-03165-w","article-title":"Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry","volume":"25","author":"Jung","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejim.2026.106852_bib0051","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s10067-024-07070-8","article-title":"Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis","volume":"43","author":"Novella-Navarro","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152572","article-title":"Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis","volume":"69","author":"Al Tabaa","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2026.106852_bib0053","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2026.106852_bib0054","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","article-title":"Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry","volume":"24","author":"Ochi","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejim.2026.106852_bib0055","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1093\/rheumatology\/kead395","article-title":"The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort","volume":"63","author":"Tomelleri","year":"2024","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.ejim.2026.106852_bib0056","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ejim.2026.106852_bib0057","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/ard.2005.050377","article-title":"Patterns of cardiovascular risk in rheumatoid arthritis","volume":"65","author":"Solomon","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0058","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar3442","article-title":"Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study","volume":"13","author":"Innala","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejim.2026.106852_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents","volume":"18","author":"Rubbert-Roth","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2026.106852_bib0060","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0061","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?","volume":"365","author":"Rothwell","year":"2005","journal-title":"The Lancet"},{"key":"10.1016\/j.ejim.2026.106852_bib0062","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2014 What is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106852_bib0063","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106852_bib0064","series-title":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022","year":"2022"},{"key":"10.1016\/j.ejim.2026.106852_bib0065","unstructured":"Italian Medicines Agency. Direct communication with healthcare professionals on Janus kinase inhibitors (JAKi) 2023. https:\/\/www.aifa.gov.it\/en\/-\/nota-informativa-importante-sugli-inibitori-della-janus-chinasi."},{"key":"10.1016\/j.ejim.2026.106852_bib0066","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526001573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526001573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:14:38Z","timestamp":1785719678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526001573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"alternative-id":["S0953620526001573"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106852","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shaping rheumatoid arthritis treatment: Clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors. Insights from the AMBI-RA study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106852"}}